A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
46-year-old Edwin Mee abused his power to bully and groom young female cadets before pouncing on them.
Two SNP members have been suspended from the party after they were part of a group of protesters who disrupted a Scottish Labour rally.
A churchgoer broke down in tears as she admitted to murdering her terminally-ill friend by smothering him to death in his care home.